Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.

Neumeyer JL, Zhang B, Zhang T, Sromek AW, Knapp BI, Cohen DJ, Bidlack JM.

J Med Chem. 2012 Apr 26;55(8):3878-90. doi: 10.1021/jm3001086. Epub 2012 Apr 4.

2.

Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.

Wang Y, Tang K, Inan S, Siebert D, Holzgrabe U, Lee DY, Huang P, Li JG, Cowan A, Liu-Chen LY.

J Pharmacol Exp Ther. 2005 Jan;312(1):220-30. Epub 2004 Sep 21.

3.

High-affinity carbamate analogues of morphinan at opioid receptors.

Peng X, Knapp BI, Bidlack JM, Neumeyer JL.

Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. Epub 2007 Jan 17.

4.

Studies of micro-, kappa-, and delta-opioid receptor density and G protein activation in the cortex and thalamus of monkeys.

Ko MC, Lee H, Harrison C, Clark MJ, Song HF, Naughton NN, Woods JH, Traynor JR.

J Pharmacol Exp Ther. 2003 Jul;306(1):179-86. Epub 2003 Apr 3.

5.

Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.

Harland AA, Yeomans L, Griggs NW, Anand JP, Pogozheva ID, Jutkiewicz EM, Traynor JR, Mosberg HI.

J Med Chem. 2015 Nov 25;58(22):8952-69. doi: 10.1021/acs.jmedchem.5b01270. Epub 2015 Nov 13.

6.

Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.

Li G, Aschenbach LC, Chen J, Cassidy MP, Stevens DL, Gabra BH, Selley DE, Dewey WL, Westkaemper RB, Zhang Y.

J Med Chem. 2009 Mar 12;52(5):1416-27. doi: 10.1021/jm801272c.

7.

Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors.

Olianas MC, Concas D, Onali P.

Br J Pharmacol. 2006 Feb;147(4):360-70.

8.

Effect of N-alkyl and N-alkenyl substituents in noroxymorphindole, 17-substituted-6,7-dehydro-4,5alpha-epoxy-3,14-dihydroxy-6,7:2',3'-indolomorphinans, on opioid receptor affinity, selectivity, and efficacy.

McLamore S, Ullrich T, Rothman RB, Xu H, Dersch C, Coop A, Davis P, Porreca F, Jacobson AE, Rice KC.

J Med Chem. 2001 Apr 26;44(9):1471-4.

PMID:
11311071
9.

Novel ligands for the opioid receptors: synthesis and structure-activity relationships among 5'-aryl and 5'-heteroaryl 17-cyclopropylmethyl-4,5 alpha-epoxypyrido[2',3':6,7]morphinans.

Ananthan S, Khare NK, Saini SK, Davis P, Dersch CM, Porreca F, Rothman RB.

Bioorg Med Chem. 2003 Sep 1;11(18):4143-54.

PMID:
12927876
10.

Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.

Zhang B, Zhang T, Sromek AW, Scrimale T, Bidlack JM, Neumeyer JL.

Bioorg Med Chem. 2011 May 1;19(9):2808-16. doi: 10.1016/j.bmc.2011.03.052. Epub 2011 Mar 26.

11.

Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.

Ananthan S, Johnson CA, Carter RL, Clayton SD, Rice KC, Xu H, Davis P, Porreca F, Rothman RB.

J Med Chem. 1998 Jul 16;41(15):2872-81.

PMID:
9667975
12.

Ligands for kappa-opioid and ORL1 receptors identified from a conformationally constrained peptide combinatorial library.

Becker JA, Wallace A, Garzon A, Ingallinella P, Bianchi E, Cortese R, Simonin F, Kieffer BL, Pessi A.

J Biol Chem. 1999 Sep 24;274(39):27513-22. Erratum in: J Biol Chem 1999 Nov 12;274(46):33177.

13.

Synthesis, opioid receptor binding, and functional activity of 5'-substituted 17-cyclopropylmethylpyrido[2',3':6,7]morphinans.

Ananthan S, Kezar HS 3rd, Saini SK, Khare NK, Davis P, Dersch CM, Porreca F, Rothman RB.

Bioorg Med Chem Lett. 2003 Feb 10;13(3):529-32.

PMID:
12565965
14.

Big dynorphin as a putative endogenous ligand for the kappa-opioid receptor.

Merg F, Filliol D, Usynin I, Bazov I, Bark N, Hurd YL, Yakovleva T, Kieffer BL, Bakalkin G.

J Neurochem. 2006 Apr;97(1):292-301. Epub 2006 Mar 3.

15.

Syntheses and opioid receptor binding affinities of 8-amino-2,6-methano-3-benzazocines.

Wentland MP, Ye Y, Cioffi CL, Lou R, Zhou Q, Xu G, Duan W, Dehnhardt CM, Sun X, Cohen DJ, Bidlack JM.

J Med Chem. 2003 Feb 27;46(5):838-49.

PMID:
12593663
16.

Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.

Neumeyer JL, Zhang A, Xiong W, Gu XH, Hilbert JE, Knapp BI, Negus SS, Mello NK, Bidlack JM.

J Med Chem. 2003 Nov 20;46(24):5162-70.

PMID:
14613319
17.
18.

Design of high affinity cyclic pentapeptide ligands for kappa-opioid receptors.

Przydzial MJ, Pogozheva ID, Ho JC, Bosse KE, Sawyer E, Traynor JR, Mosberg HI.

J Pept Res. 2005 Nov;66(5):255-62.

PMID:
16218993
19.

Analysis of [3H]bremazocine binding in single and combinatorial opioid receptor knockout mice.

Simonin F, Slowe S, Becker JA, Matthes HW, Filliol D, Chluba J, Kitchen I, Kieffer BL.

Eur J Pharmacol. 2001 Mar 2;414(2-3):189-95.

PMID:
11239918
20.

High-affinity mu opioid receptor ligands discovered by the screening of an exhaustively stereodiversified library of 1,5-enediols.

Harrison BA, Gierasch TM, Neilan C, Pasternak GW, Verdine GL.

J Am Chem Soc. 2002 Nov 13;124(45):13352-3.

PMID:
12418865
Items per page

Supplemental Content

Write to the Help Desk